[Proneuron1] Proneuron's ProCord Granted European Patent

[proneuron1 at list.proneuron.com]

PRONEURON'S PROCORD GRANTED EUROPEAN PATENT
ProCord is an experimental procedure for the treatment of 
complete spinal cord injury now being studied in an international Phase II
trial.

L.A., California, March 23, 2005 --- Proneuron Biotechnologies
(www.proneuron.com) announced today the grant of the European patent for
ProCord (autologous incubated macrophages) for the treatment of acute spinal
cord injury by the European Patent Office. European Patent number EP 0952772
B1, dated 16 March 2005, for the use of, mononuclear phagocytes to promote
axonal regeneration, was granted to Yeda Research and Development Co. Ltd.
from which Proneuron Biotechnologies has an exclusive license. The main
inventor is Proneuron Scientific Founder Professor Michal Schwartz of the
Weizmann Institute of Science. ProCord was previously patented in the U.S.
under US 5,800,812, dated 1 September 1998, US 6,117,424, dated 12 September
2000 and US 6,267,955, dated 31 July 2001, and received an orphan drug
designation by the FDA in September 2004.
	
"The patent granted by the European Patent Office (EPO) is yet another brick
in the road towards developing a potential treatment for spinal cord injury.
It is our intention to continue working hard to determine how to most
effectively use macrophages (special type of white blood cell) to introduce
a beneficial immune reaction to an immune restricted area such as the
central nervous system," said Professor Schwartz.

Proneuron is currently engaged in a Phase II international, multi-center,
randomized controlled study of ProCord. Potential candidates must be
enrolled within 12 days of injury in order to receive the treatment within
the 14-day window of the clinical trial. For additional information as well
as a complete list of sites and clinical teams please visit:
www.spinalcordtrial.com.

"This is an important patent for several reasons. First, following the
patents of ProCord in the U.S., it lends further support to the concept of
using macrophages and or dendritic cells to induce spinal cord injury
recovery.  The EP patent also comes at a time when the Phase II study is
moving ahead at a particularly aggressive pace at trial sites in the U.S.
and Israel, the latter of which serves as the designated enrollment site for
patients from Europe. It is our hope that this news will encourage the
medical community in Europe to more actively join in this research effort,"
said Proneuron CEO Mr. Nir Nimrodi.

PATIENT, IMMEDIATE FAMILY OF PATIENT AND/OR PHYSICIAN INQUIRIES:
	24 hour a day Patient Recruitment Center:
	Email: clinical.trial at proneuron.com 
	Telephone: 1 866 539 0767 (U.S. toll free) or 1 506 652 3486. 
	Fax: 1 866-214-7078
*Callers outside of the U.S., please use standard international dialing code

Proneuron Biotechnologies Inc. is a privately held biopharmaceutical company
developing products for the medical treatment of spinal cord injuries and
other disorders of the central nervous system. Its products are based on
proprietary technology licensed from Yeda for modulating the interaction
between the nervous and immune systems. The company's products are currently
being evaluated in several clinical studies located in the U.S., Belgium and
Israel. These include: an independently managed, international,
multi-center, randomized-controlled Phase II trial of ProCord, autologous
incubated macrophages, an experimental procedure for spinal cord injuries
and a Phase II program of Cop-1 for the treatment of Huntington's disease
(HD), Glaucoma and other neurodegenerative diseases. The latter is being
managed by Teva as part of the Proneuron's strategic collaboration for
development and commercialization of Cop-1 for various neurodegenerative
indications. The Company is also developing PN277 for the treatment of
additional neurodegenerative diseases.

For additional information, please contact Marjie Hadad, Media Liaison,
Proneuron, Marjie.hadad at proneuron.com or at +972-54-536-5220.